Avatar

Treatment of Relapsed Myeloma: Overview of Approved Drugs & Optimal Sequencing

By Morie Gertz 11 Videos
March 25, 2020
3 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
15:24
SOHO 3rd Italian Conference

SOHO Italy 2021 on R/R MM Treatment in Europe

Feat. C. Cerchione
17:47
SOHO 3rd Italian Conference

SOHO Italy 2021 on MM: State of the Art Therapy in Europe

Feat. C. Cerchione
01:29
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on the Addition of Carfilzomib as a Thir…

Feat. C. Cerchione
16:57
SOHO Italy 1st School of Multiple Myeloma

Anti-CD38 in MM Daily Practice: How Can We Potentiate the Action of …

Feat. C. Cerchione
06:50
ecancer

EHA 2021 Highlights on KRd for Lenalidomide-Refractory MM

Feat. C. Cerchione
19:13
SOHO Italy 1st School of Multiple Myeloma

Daratumumab in MM Daily Practice: Is It Becoming the New Backbone?

Feat. C. Cerchione
15:57
SOHO 3rd Italian Conference

SOHO Italy 2021 on CAR T in MM: Preliminary Data and Perspectives

Feat. C. Cerchione
17:29
SOHO Italy 1st Clinical and Biological School of CAR-T

How to Integrate CAR-T in the Clinical Scenario of Multiple Myeloma

Feat. C. Cerchione
26:05
SOHO Italy 1st School of Multiple Myeloma

Introducing Anti-CD38 in Daily Practice of MM: Updates on the GRIFFI…

Feat. C. Cerchione
15:12
Yale Cancer Center

ASH 2021: Cellular Therapies in Myeloma

Feat. N. Bar
10:50
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on the Efficacy and Safety of Cilta-Cel in R/R MM: …

Feat. A. Jakubowiak
33:28
Cleveland Clinic Taussig Cancer Institute

Management of Relapsed/Refractory Multiple Myeloma

Feat. F. Anwer
04:41
Joshua Richter

Examining Triplet Therapy in MM: Analysis of ELOQUENT-3 and MAIA Tri…

31:15
Claudio Cerchione

R/R MM State of the Art: Proteasome Inhibitors, IMiDs, HDACi, mAbs, …

23:18
Oncology Data Advisor

Can Diet and Nutrition Impact Multiple Myeloma Outcomes?

Feat. U. Shah, R. Banerjee
26:02
Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

2022 Novel Immune-Based Therapy for R/R MM: Interactive Case Discuss…

Feat. J. Brayer
22:41
Ehsan Malek

Importance and Prospect of Maintenance Treatment in Post-SCT MM Pati…

25:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases

MM - Overview of Trials Presented at ASH 2018

Feat. A. Abdallah
08:15
2018 Pan Pacific Lymphoma Conference

Evolution of Myeloma Induction Regimens

Feat. S. Holstein
14:15
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

MRD in Multiple Myeloma Isn't Ready for Prime Time: More Patient…

Feat. T. Martin